Bipartisan lawmakers introduced legislation to establish a National Biopharmaceutical Manufacturing Center of Excellence as a public‑private partnership to advance domestic biomanufacturing, improve regulatory understanding of innovative processes, and train a skilled workforce. Sponsors include Sens. Coons and Budd and a coalition of House members. The proposal draws on recommendations from the National Security Commission on Emerging Biotechnology and aims to reduce supply‑chain reliance on foreign APIs and biologics, support CGMP‑compliant pilot facilities, and accelerate scale‑up for critical medicines and advanced modalities. If enacted, the COE could catalyze investment in domestic capacity, influence site selection for manufacturing, and shape workforce pipeline programs — important levers for national health security and industrial policy in biotech.